Biography
Arturo joined Wellington Partners in 2019 and was promoted to Senior Associate in 2020 and Principal in 2022. Arturo currently serves as Head of Business Development at gene-editing newco and acts as a venture advisor on topics related to advanced therapies, R&D tools, industrial biotechnology, and techbio.
At Wellington, Arturo has been actively involved in several investments, including Ayoxxa, Carisma, eGenesis, Genkyotex, Koa Health, SNIPRBiome, Themis Biosciences, and gene-editing newco.
Prior to joining Wellington, Arturo worked as an Investment Analyst in the life science team of M Ventures in the Netherlands, where he helped to define business strategies for potential spin-offs and was involved in several investment processes, including Riffyn, Plexium, Pantheon Biosciences, and DNA Script. Prior to joining M Ventures, Arturo completed his post-doctoral studies, developing synthetic biology approaches for type 1 diabetes treatments and bioindustrial applications while freelancing in different start-ups supporting them with strategy and business development.
Arturo holds an MSc in biomedical research and a Ph.D. in biomedicine from Pompeu Fabra University in Barcelona, Spain, in the fields of cell signaling, synthetic biology, and biological computation, as well as an MBA from UPF Barcelona School of Management. He performed additional research in the Folch Lab at the University of Washington, Seattle, in the fields of 3D printing and microfluidics, resulting in several publications in prestigious journals.
During his academic trajectory, he received multiple distinctions such as a national graduation award (ranked 1st in Biomedical Sciences in Spain), La Caixa PhD fellowship, EMBO short-term fellowship, and an extraordinary PhD award.
Besides his activities at Wellington Partners, Arturo is actively involved in the European life science start-up ecosystem, mentoring within different programs, including the BII Advisory Group and CaixaResearch Consolidate.